

1 **Title:**

2 COVID-19 vaccine breakthrough infections among fully vaccinated Health Care Workers in
3 Lagos, Nigeria

4 **Short title**

5 COVID-19 vaccine breakthrough infection in Lagos

6 **Authors:**

7 David A. Oladele¹, Abideen Salako¹, James Ayorinde², Chika Onwuamah³, Olagoke Usman⁴,
8 Rufai Abubakar¹, Gideon Liboro³, Oluwatosin Odubela¹, Sunday Mogaji⁴, Fehintola Ige³,
9 Gregory Ohihoin¹, Oliver Ezechi¹, Rosemary Audu³, Richard A. Adegbola³, Adedamola
10 Dada⁴, Tunde Salako¹

11

12 **Authors Affiliation:**

- 13 1. Clinical Sciences Department, Nigerian institute of Medical Research, Yaba, Lagos
14 2. Biochemistry Department, Nigerian institute of Medical Research, Yaba, Lagos
15 3. Microbiology Department, Nigerian institute of Medical Research, Yaba, Lagos
16 4. Federal Medical Centre, Ebute Meta, Lagos

17

18 Corresponding Author:

19 David A. Oladele

20 Email: daveohlay@yahoo.com

21

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 **Abstract:**

23 Background: Access to vaccines has contributed to the control of COVID-19. However,
24 evaluation of the effectiveness of the vaccines in a setting where the vaccines were not
25 originally tested is critically important. This study evaluates the clinical and laboratory
26 characteristics of COVID-19 vaccine breakthrough infections among healthcare workers
27 (HCWs).

28 Methods: A multicentre prospective study among HCWs who had two doses of the
29 Oxford/AstraZeneca ChAdOx1-S [recombinant] (AZD1222) vaccine were followed up 24
30 weeks. Nasopharyngeal and oropharyngeal specimens were tested using RT-PCR for SARS-
31 CoV-2 and positive samples were subjected to whole genome sequencing for variant
32 assignment.

33 Result: A total of 369 HCWs were enrolled; of which 24 (6.5%) had breakthrough infections.
34 There was equal sex distribution among the breakthrough cases. The majority were aged
35 between 30 to 39years (37.5%), and had mild symptoms of cough, fever, headache, and
36 nausea/vomiting (58%), with no hospitalization. Among the 24 breakthrough cases whose
37 whole genomes were successfully sequenced, three were confirmed to be Delta B.1.617.2
38 variant during the 3rd wave and an additional three were confirmed as omicron B.1.1.529
39 variant during the 4th wave.

40 Conclusion: We reported vaccine breakthrough cases among fully vaccinated HCWs with the
41 majority presenting with mild illness. Both delta and omicron variants were identified during
42 the different epidemiologic spectrums of SARS-CoV-2. Therefore, there is a need to scale up
43 vaccination for all front-line health workers and high-risk populations in developing countries.

44 Keywords: COVID-19, SARS-CoV-2, Vaccine breakthrough infections, Nigeria, SSA

45

46 **Introduction**

47 Ever since the outbreak of Coronavirus disease (COVID-19) caused by Severe Acute
48 Respiratory Syndrome Coronavirus 2 (SARS-COV-2), all effort has been geared toward
49 finding an effective vaccine to curtail the spread of the virus [1]. As of 1st April 2022, there
50 were 153 candidate vaccines against SARS-CoV-2 in the clinical development phase and 196
51 candidate vaccines in the preclinical development phase, and a total of 8 have been granted
52 Emergency Use Listing (EUL) by the WHO globally [2,3]. Four randomized controlled trials
53 carried out in the United Kingdom, South Africa, and Brazil reported the safety and efficacy
54 of the AZD1222 vaccine against SARS-CoV-2 [4]. The efficacy of AZD1222 was 63.09%
55 against symptomatic infection [5]. However, longer dosage intervals between doses (8-
56 12weeks) are associated with greater vaccine efficacy [4].

57 In the mid of the first quarter of 2021, AZD1222 arrived in Nigeria. However, due to limited
58 doses available, it was recommended that priority be given to health care workers (HCWs) at
59 high risk of exposure and the elderly who were considered a high-risk population for morbidity
60 and mortality from the COVID-19 [5]. The HCWs were also considered a high-risk group
61 because an asymptomatic infected person may cause a horizontal spread of the virus during the
62 cause of work and the vaccine has been shown to reduce the incidence of asymptomatic
63 infection and the associated infectivity [6].

64 However, breakthrough infections have been reported globally among the HCWs that have
65 been fully vaccinated [7,8]. A breakthrough infection was defined as the detection of SARS-
66 CoV-2 on RT-PCR assay performed 11 or more days after receipt of the second dose
67 of ChAdOx1-S if no explicit exposure or symptoms had been reported during the first 6
68 days. Some studies have shown that breakthrough cases of COVID-19 are associated with
69 asymptomatic infection or milder symptoms. Other studies have implicated a different variant

70 of SARS-COV-2 following vaccination (Alpha/UK variant B.1.1.7, Beta/South African
71 B.1.351, Gamma/Brazilian variant, and the Kappa/Delta B.1.617.1/B.1.617.2 variants) as the
72 cause of the breakthrough infection [9]. Therefore, vaccinated individuals are still advised to
73 maintain and strengthen public health measures (masking, physical distancing, hand washing,
74 respiratory and cough hygiene, avoiding crowds, and ensuring good ventilation), especially
75 when in confined spaces to adequately protect themselves and loved ones [10]. There is a
76 paucity of data on COVID-19 vaccine breakthrough cases in low and middle-income countries.
77 Following the rollout of the Oxford Astrazeneca ChAdOx1-S [recombinant] vaccine in Lagos
78 State, Nigeria, we undertook a study to evaluate SARS-CoV-2 breakthrough infections among
79 fully vaccinated HCWs in two healthcare centers in Lagos and report our findings as part of a
80 study designed to study the effectiveness of COVID-19 vaccination in HCWs.

81

82 **Methods**

83 Study locations and enrolment procedure:

84 The study was conducted among the fully vaccinated HCWs of two health facilities in Lagos:
85 The Nigerian Institute of Medical Research, (NIMR) Yaba, and the Federal Medical Center,
86 (FMC) Ebute Metta). A total of 50 and 319 HCWs at FMC and NIMR respectively who had
87 received two doses of AZD1222 at intervals of 12 weeks were followed up 24 weeks after
88 receiving the second dose (Fig 1: Study timeline).

89 Healthcare workers who consented to be part of the COVID-19 vaccine effectiveness study
90 and who received 2 doses of the COVID-19 vaccines at the 2 facilities were recruited into the
91 study. Participants with confirmed breakthrough infection were interviewed using an adapted
92 questionnaire for public health investigation of COVID-19 vaccine breakthrough cases [11].

93 Nasopharyngeal and oropharyngeal swabs of all vaccinated HCWs were taken at 4 to 6 weeks,
94 8 to 12 weeks, and 16-24 weeks following the second dose of the vaccine and tested for the
95 presence of SARS-CoV-2 using reverse-transcriptase– polymerase-chain-reaction (RT-PCR)
96 assay. HCWs who had COVID-19-related symptoms or were exposed to infected persons
97 voluntarily presented to the NIMR for testing. We identified a breakthrough infection as the
98 detection of SARS-CoV-2 infection in individuals, who have been fully vaccinated against
99 COVID-19. The identified breakthrough cases were interviewed using a questionnaire for
100 investigation of COVID-19 vaccine breakthrough cases adapted from the Centers for Disease
101 Control and Prevention (CDC) protocol, we were able to describe the clinical profile of those
102 with breakthrough infections.

103 Laboratory Methods:

104 Swab samples collected were tested using Cobas® SARS-CoV-2 qualitative assay on Cobas®
105 6800 System (Roche Molecular Systems, Rotkreuz, Switzerland) for the detection of the 2019
106 novel coronavirus (SARS-CoV-2) RNA [12].

107 Briefly, oropharyngeal and nasopharyngeal swabs were collected by trained personnel, and
108 RT-PCR testing was performed with the use of the **Cobas®** SARS-CoV-2. **Cobas®** SARS-
109 CoV-2 testing is based on fully automated sample preparation (nucleic acid extraction and
110 purification) followed by PCR amplification and detection. Automated data management was
111 performed by the **Cobas®** 6800/8800 software which assigns test results for all tests.

112 Selective amplification of target nucleic acid from the sample is achieved by the use of target-
113 specific forward and reverse primers for ORF1 a/b non-structural region unique to SARS-CoV-
114 2. Additionally, a conserved region in the structural protein envelope E-gene was chosen for
115 pan-Sarbecovirus detection. The pan-Sarbecovirus detection sets also detected the SARS-CoV-

116 2 virus. Selective amplification of RNA Internal Control is achieved by the use of non-
117 competitive sequence-specific forward and reverse primers that have no homology with the
118 coronavirus genome.

119 Complete genome sequencing of SARS-CoV-2 positive samples was done using
120 the ATOplex RNA Universal Library Preparation module developed by MGI Co. Ltd (China)
121 [13]. In brief, extracted viral RNA samples were converted to cDNA which was used
122 to generate tiling PCR amplicons. Dual barcodes for each specimen were enzymatically
123 tagged to end-repaired amplicons. Cleaned libraries were pooled, denatured, circularized,
124 and amplified using rolling circle amplification (RCA) to generate DNA nanoballs (DNB).
125 Normalized DNB libraries were sequenced using paired end DNBSEQ-G50RS High-
126 throughput Sequencing kit with a large flow cell (FCL PE100) [14].

127

128 Ethical consideration:

129 Ethical approval for the study was obtained from the Institutional Review Board of the Nigerian
130 Institute of Medical Research (IRB-21-040) and written informed consent was obtained from
131 all the study participants prior to enrolment in the study.

132

133 Data processing and Analysis:

134 The MGI SARS-CoV-2 bioinformatics analysis pipeline in GitHub [15] was used to perform
135 the quality assessment of the de-multiplexed reads and to generate consensus sequences in
136 FASTA format. For all analyses, default parameters were used. The complete genome
137 sequences of each of the SARS-CoV-2 isolates were submitted to PANGOLIN (web-based)
138 for lineage assignment [16].

139 Data management and analysis were done using SPSS version 23. Descriptive statistic was
140 done to adequately document the clinical and laboratory characteristics of the breakthrough
141 cases.

142 **Results**

143 The socio-demographic characteristics of persons with breakthrough infections are shown in
144 table 1. Among 369 fully vaccinated HCWs in the two health facilities, 24 (6.5%) breakthrough
145 cases were detected with equal sex distribution (50%) and the age ranging from 30 to 39 years
146 with a mean of 38.7 years.

147 A review of the job description of participants shows that 8 of the breakthrough cases work at
148 the various laboratory complexes, 4 hold various administrative duties, 3 were data officers
149 managing hospital databases, 2 were COVID-19 drive-through test center staff, and 2 were
150 staff of maintenance department. Others did include a medical doctor, a pharmacist, a
151 physiotherapist, and a psychologist.

152

153 Table 1: Table 1: Socio-demographic characteristics of the 24 persons with breakthrough
154 infection

Variable	Number (%)
Age (years)	
20-29	5 (20.8)
30-39	9 (37.5)
40-49	7 (29.2)
50-65	3 (12.5)
Mean Age	38.7
Sex	

Female	12 (50.0)
Male	12 (50.0)
Place of practice	
NIMR	18 (75.0)
FMC	6 (25.0)
Job description of the HCW	
Laboratory staff	8 (33.3)
Admin staff	4 (16.7)
Data officer	3 (12.5)
COVID-19 test centre staff	2 (8.3)
Works/maintenance	2 (8.3)
Doctor	1 (4.2)
Pharmacist	1 (4.2)
Psychologist	1 (4.2)
Physiotherapist	1 (4.2)
Biotech(MBT) staff	1 (4.2)

155

156 Evaluation of the spectrum of COVID-19 symptoms among the 24 breakthrough cases,
157 revealed that 14 had mild symptoms and 10 participants were asymptomatic (Table 2). Some
158 of the reported symptoms include cough (41.7%), fever (33.3%), headache (29.2%), chills
159 (12.5%) nausea and vomiting (12.5%), and fatigue (8.3%). Most of the reported symptoms
160 did not require hospital admission though about 16.7% of the symptomatic cases required
161 outpatient care. Others were treated at home using over-the-counter medications. There was
162 no history of hospitalization, need for breathing support, or oxygen use, and no history of
163 death among the breakthrough cases. Also, none of the symptomatic cases had a history of
164 immunosuppressive disease or are on immunosuppressive therapy.

165

166

167

168 Table 2: Clinical symptoms of the participants with breakthrough infection

Clinical symptoms	Frequency(percentage)
Fever	8 (33.3)
Chills	3 (12.5)
Rigor	0 (0.0)
Myalgia	2 (8.3)
Headache	7 (29.2)
Sore throat	2 (8.3)
Nausea and vomiting	3 (12.5)
Diarrhea	1 (4.2)
Fatigue	2 (8.3)
Congestion/ runny nose	2 (8.3)
Cough	10 (41.7)
Chest pain	1 (4.2)
New taste disorder	1 (4.2)

169

170 On follow-up assessment, all the breakthrough cases recovered fully the following self-
171 isolation for 2 weeks and a repeat of the nasopharyngeal and oropharyngeal swab for RT PCR
172 for each one was all negative. Nine of the samples from the breakthrough cases reported during
173 the second follow-up period (3rd wave of COVID-19 infection in Nigeria) were sequenced at
174 the Central Laboratories at NIMR using the next-generation sequencing. Lineage assignment
175 using Pangolin did show that three of the breakthrough cases are B.1.617.2 Delta variant. Also,
176 six of the breakthrough cases reported during the 3rd follow-up period (Corresponding to the
177 4th wave of COVID-19 in Nigeria) were sequenced and three were confirmed as
178 Omicron B.1.1.529 variant while the remaining three samples could not be sequenced because
179 the CT values were above 34.

180

181 Discussion

182 Since the emergency use listing (EUL) of different COVID-19 vaccines by the WHO, there
183 has been a considerable drop in the number of persons with severe disease, hospitalization, and
184 death [17]. Several studies have reported a reduction in the neutralization potential of the sera
185 of individuals vaccinated, hence the risk of breakthrough infection [18]. This study, therefore,
186 describes the clinical and laboratory spectrum of COVID-19 vaccine breakthrough cases in
187 Lagos, Nigeria. There were 24 vaccine breakthrough infections among the 369 fully vaccinated
188 health care workers enrolled during the period of this study. Equal sex distribution was
189 observed (50.0%) among participants with breakthrough infection and the cases occurred
190 among participants who work as a laboratory staff (33.3%), administrative staff (16.7%), data
191 officers (12.5%), COVID-19 test center staff (8.3%) and maintenance department staffs
192 (8.3%).

193 The findings in our study are different from the reported predominant health workers with
194 vaccine breakthrough cases in previous works [19-24]. For instance, a study from Vietnam
195 reported a greater proportion (8%) of vaccine breakthrough cases among healthcare workers
196 [25].

197 The majority of the HCWs had mild symptoms which do not require hospitalization, ranging
198 from cough (41.7%), fever (33.3%), and headache (29.2%). This finding is similar to another
199 report of COVID-19 vaccine breakthrough cases reported from China in which most of the
200 cases were either asymptomatic or with mild symptoms not requiring hospitalization [25]. A
201 similar study in Israel showed a percentage breakthrough case of 2.6% (out of 1,497 HCWs
202 tested) among HCWs, the majority having milder symptoms. However, a few were noted to
203 have required hospitalization (9.8%) with full recovery after 6 weeks [23]. Also, studies in
204 Kerala and Delhi, India reported mild symptoms among the COVID-19 vaccine breakthrough

205 cases in their setting. [24]. Thus, the vaccine reduces the severity of the infection, the need for
206 hospitalization, and mortality. Therefore, enhancing the vaccination drive and immunizing the
207 populations quickly would be an important strategy to prevent further morbidity and mortality
208 from the COVID-19 and would reduce the burden on the health care system.

209 The Delta variant has been designated as a variant of concern due to increased transmission
210 and higher immune evasion [19]. The emergence of a variant of concerns has led to an upsurge
211 in COVID-19 cases and the second wave of pandemics globally. Incidentally, several countries
212 have reported COVID-19 breakthrough infections even after completion of the full vaccination
213 schedule [20,21]. Over 10,000 breakthrough infections after completion of the full course of
214 vaccination, representing less than 1 % of the vaccinated population have been reported in the
215 USA [22]. Overall, breakthrough infections were seen in a smaller percentage of the total
216 vaccinated population. Our study report complete-genome sequences among the vaccine
217 breakthrough cases seen during the 3rd wave and 4th wave of the COVID-19 infection in
218 Nigeria in which three cases were Delta variant (B.1.617.2) during the 3rd wave and 3 were
219 omicron during the 4th wave. This is similar to reports from other parts of the world in which
220 the delta and the omicron variants were reported as the predominant variants in the 3rd and
221 4th wave of COVID-19 respectively [26-28].

222 The strength of the study includes the fact that it was carried out among high-risk
223 individuals(HCWs) and the availability of PCR testing and genomic sequencing facility which
224 helped in the diagnosis and characterization of the prevalent SARS-CoV-2 variants in
225 Nigeria. To the best of our knowledge, this is the first report of vaccine breakthrough infections
226 among HCWs after completion of the full course of COVID-19 vaccination in Nigeria. Our
227 study has several limitations including lacking the capability to carry out real-time neutralizing

228 antibody tests among the vaccine breakthrough cases and the inability to perform complete
229 genome sequencing for all the vaccine breakthrough cases.

230

231 **Conclusions:**

232 With the availability of the COVID-19 vaccine in Nigeria, the front-line health worker was the
233 priority group for vaccination. We reported vaccine breakthrough cases among fully vaccinated
234 HCWs, and the spectrum of the clinical presentation was asymptomatic to mild cases without
235 any hospitalization and mortality. There is a need to scale up vaccination of all front-line health
236 workers in developing countries as well as other high-risk populations.

237

238 **Authors contribution:**

239 Designing research studies: DAO,RA,RAA

240 Laboratory analysis: JA,CO,GL,FI

241 Acquiring data: DAO,OU,RA,GL,OO,SM

242 Analysing data: DAO,GO,RA,RA

243 Writing the manuscript: DAO,JA,OE,RA,RAA,AD,BS

244

245

246

247

248

249 **References**

- 250 **1.** Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a
251 nationwide mass vaccination setting. *N Engl J Med* 2021; 384:1412-23.
- 252 **2.** World Health Organization. COVID-19 vaccine tracker and landscape Geneva,
253 Switzerland: World Health Organization; 2022 [Available from:
254 [https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines)
255 vaccines
- 256 **3.** [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines)
257 vaccines)
- 258 **4.** [www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-](http://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials)
259 materials. Interim recommendations for use of the AZD1222 (ChAdOx1-S
260 [recombinant]) vaccine against COVID19 developed by Oxford University and
261 AstraZeneca, Interim guidance 10 February 2021
- 262 **5.** www.who.int/news-room/feature-stories/detail: The Oxford/AstraZeneca COVID-19
263 vaccine: what you need to know.
- 264 **6.** Rivett L, Sridhar S, Sparkes D, et al. Screening of HCWs for SAR-COV-2 highlights
265 the role of asymptomatic carriage in covid-19 transmission. *Elife*.2020;11:9.
- 266 **7.** Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., ... & Regev-
267 Yochay, G. (2021). Covid-19 breakthrough infections in vaccinated health care
268 workers. *New England Journal of Medicine*, 385(16), 1474-1484
- 269 **8.** Liu, C., Lee, J., Ta, C., Soroush, A., Rogers, J. R., Kim, J. H., ... & Weng, C. (2021).
270 A retrospective analysis of COVID-19 mRNA vaccine breakthrough infections-risk
271 factors and vaccine effectiveness. medRxiv.
- 272 **9.** Yadav P.D, Nyayanit D.A, Sahay RR, Sarkale P, Pethani J, Patil S, Baradkar S,
273 Potdar V, Patil DY. Isolation and characterization of the new SAR-COV-2 variant in


- 274 travellers from the UK to India; VUI-202012101 of the B.1.1.7 lineage. *J Travel med*,
275 2021, 28, taab009, doi: 10.1093/jtm/taab009.
- 276 10. Calistri P, Amato L, Puglia I, et al. Infection sustained by lineage B.1.1.7 of SARS-
277 COV-2 is characterised by longer persistence and higher viral RNA loads in
278 nasopharyngeal swab. *Int J infect. Dis.* 2021; 105:753-755.
- 279 11. Centers for Disease Control and Prevention. (2021). Public health investigations of
280 COVID-19 vaccine breakthrough cases: Case investigation protocol.
281 [https://www.cdc.gov/vaccines/covid-19/downloads/covid-vaccine-breakthrough-case-](https://www.cdc.gov/vaccines/covid-19/downloads/covid-vaccine-breakthrough-case-investigations-protocol.pdf)
282 [investigations-protocol.pdf](https://www.cdc.gov/vaccines/covid-19/downloads/covid-vaccine-breakthrough-case-investigations-protocol.pdf)
- 283 12. Wirden, M., Feghoul, L., Bertine, M., Nere, M. L., Le Hingrat, Q., Abdi, B., ... &
284 Chaix, M. L. (2020). Multicenter comparison of the Cobas 6800 system with the
285 RealStar RT-PCR kit for the detection of SARS-CoV-2. *Journal of Clinical Virology*,
286 130, 104573.
- 287 13. Qin, Y., Koehler, S., Zhao, S., Mai, R., Liu, Z., Lu, H., & Xing, C. (2021). High-
288 throughput low-cost DNA sequencing using surface-coating technology.
- 289 14. Reference: Xiao, M., Liu, X., Ji, J. et al. Multiple approaches for massively parallel
290 sequencing of SARS-CoV-2 genomes directly from clinical samples. *Genome Med*
291 12, 57 (2020). <https://doi.org/10.1186/s13073-020-00751-4>
- 292 15. https://github.com/MGI-tech-bioinformatics/SARS-CoV-2_Multi-PCR_v1.0
- 293 16. Áine O'Toole, Emily Scher, Anthony Underwood, Ben Jackson, Verity Hill, John T
294 McCrone, Rachel Colquhoun, Chris Ruis, Khalil Abu-Dahab, Ben Taylor, Corin
295 Yeats, Louis du Plessis, Daniel Maloney, Nathan Medd, Stephen W Attwood, David
296 M Aanensen, Edward C Holmes, Oliver G Pybus, Andrew Rambaut, Assignment of
297 epidemiological lineages in an emerging pandemic using the pangolin tool, *Virus*

- 298 Evolution, Volume 7, Issue 2, December 2021, veab064,
299 <https://doi.org/10.1093/ve/veab064>
- 300 17. Rinott, E., Youngster, I., & Lewis, Y. E. (2021). Reduction in COVID-19 patients
301 requiring mechanical ventilation following implementation of a national COVID-19
302 vaccination program—Israel, December 2020–February 2021. *Morbidity and*
303 *Mortality Weekly Report*, 70(9), 326.
- 304 18. Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., ... &
305 Screaton, G. R. (2021). Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine
306 and convalescent serum. *Cell*, 184(16), 4220-4236.
- 307 19. Nivedita Gupta¹ , Harmanmeet Kaur¹ , Pragya Yadav² *, Labanya Mukhopadhyay¹ ,
308 Rima R Sahay² , et al.. Clinical characterization and Genomic analysis of COVID-19
309 breakthrough infections during second wave in different states of India.
310 Doi:2021.07.13.21260273; July 15, 2021.
- 311 20. Hacısuleyman, E.; Hale, C.; Saito, Y.; Blachere, N.E.; Bergh, M.; Conlon, E.G.;
312 SchaeferBabajew, D.J.; DaSilva, J.; Muecksch, F.; Gaebler, C.; et al. Vaccine
313 Breakthrough Infections with SARS-CoV-2 Variants. *N. Engl. J. Med.* 2021, 384,
314 2212–2218, doi:10.1056/NEJMoa2105000.
- 315 21. Keehner, J.; Horton, L.E.; Pfeffer, M.A.; Longhurst, C.A.; Schooley, R.T.; Currier,
316 J.S.; Abeles, S.R.; Torriani, F.J. SARS-CoV-2 Infection after Vaccination in Health
317 Care Workers in California. *N. Engl. J. Med.* 2021, 384, 1774–1775,
318 doi:10.1056/NEJMc2101927.
- 319 22. CDCMMWR COVID-19 Vaccine Breakthrough Infections Reported to CDC —
320 United States, January 1–April 30, 2021. *MMWR Morb. Mortal. Wkly. Rep.* 2021,
321 70, doi:10.15585/mmwr.mm7021e3.

- 322 23. Moriah B, Tal G, Yaniv L, Sharon A, Marc L, Carmit C, Michal M, Einav G.L,
323 Carmit R, Victoria I, Ilana T, Malka Z, Neta Z, Adina B, Yitshak K and Gili R.
324 Covid-19 Breakthrough Infections in Vaccinated Health Care Worker, The New
325 England Journal of Medicine, DOI: 10.1056/NEJMoa2109072, July 28, 2021.
- 326 24. Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody
327 positive compared with antibody-negative health-care workers in England: a large,
328 multicentre, prospective cohort study (SIREN). *Lancet* 2021;397:1459-69.
- 329 25. Chau, N. V. V., Ngoc, N. M., Nguyet, L. A., Quang, V. M., Ny, N. T. H., Khoa, D.
330 B., ... & OUCRU COVID-19 research group. (2021). An observational study of
331 breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare
332 workers in Vietnam. *EClinicalMedicine*, 41, 101143.
- 333 26. Christensen, P. A., Olsen, R. J., Long, S. W., Subedi, S., Davis, J. J., Hodjat, P., ... &
334 Musser, J. M. (2021). Delta variants of SARS-CoV-2 cause significantly increased
335 vaccine breakthrough COVID-19 cases in Houston, Texas. *The American Journal of*
336 *Pathology*.
- 337 27. Chia, P. Y., Ong, S. W. X., Chiew, C. J., Ang, L. W., Chavatte, J. M., Mak, T. M., ...
338 & Young, B. E. (2021). Virological and serological kinetics of SARS-CoV-2 Delta
339 variant vaccine-breakthrough infections: a multi-center cohort study. *MedRxiv*
- 340 28. Gajanan N Sapkal, PhD, Pragya D Yadav, PhD, Rima R Sahay, MD, Gururaj
341 Deshpande, PhD, Nivedita Gupta, MD, PhD, et al. Balram Bhargava, DM,
342 Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-
343 recovered vaccinated individuals, *Journal of Travel Medicine*, Volume 28, Issue 7,
344 October 2021, taab119, <https://doi.org/10.1093/jtm/taab119>

345

346



Figure